Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 30;9:22. doi: 10.3389/fonc.2019.00022

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Chuang, Wang, Niu, Zhen, Huang, Hsiao and Yang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Recovery of the proliferative activity of lung cancer cells after PF-573228 withdrawal. (A) The population of SA-β-gal-positive A549 cells declined after the cells were released from PF-573228 inhibition. (B) The proportion of SA-β-gal-positive A549 cells was ~80% when cells were exposed to PF-573228, and only 25% after PF-573228 withdrawal. (C) Initially, the cells were senescent, and proliferation ceased in the three lung cancer cell lines with PF-573228 treatment. After PF-573228 withdrawal, the A549 cells grew exponentially, H1299 cells grew linearly, and H460 cells continued to exhibit cessation of division. (D) When cells were exposed to PF-573228, cyclin B1 expression level was extremely low. After the cells were released from PF-573228 inhibition, cyclin B1 levels gradually increased in A549 cells and H1299 cells. However, cyclin B1 remained at low levels in H460 cells after PF-573228 withdrawal. ^*P < 0.05.